 we report financial results for the fourth quarter and year ended on march 7, 2016. 
 we also provide an update on the status of our clinical programs for both ARX-04 and zalviso. 
 we also provide an outlook for 2016 and discuss our plans for commercial activities.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7    # 1#2#3@xmath0#1    # 2    # 3    # 4    # 5    # 6    # 7    # 8    # 9    # 10    # 11    # 12    # 13    # 1    # 1    # 2    # 1    # 3    # 1   # 2    # 1 # 2    # 3  